Protein / target
Follicle-stimulating hormone receptor
Protein at a glance
Biological role
Follicle-stimulating hormone receptor
Strongest disease association
Ovarian hyperstimulation syndrome
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
G protein-coupled receptor for follitropin, the follicle-stimulating hormone.
View complete UniProt function annotationHide complete annotation
G protein-coupled receptor for follitropin, the follicle-stimulating hormone (PubMed:11847099, PubMed:24058690, PubMed:24692546). Through cAMP production activates the downstream PI3K-AKT and ERK1/ERK2 signaling pathways (PubMed:24058690)
Subcellular location
Domains and Gene Ontology detail (22)Hide
Domains & features
Gene Ontology
- Ccell surface
- Cendosome
- Cmembrane
- Cplasma membrane
- Creceptor complex
- Ffollicle-stimulating hormone receptor activity
- FG protein-coupled peptide receptor activity
- Fpeptide hormone binding
- Padenylate cyclase-activating G protein-coupled receptor signaling pathway
- Pcellular response to follicle-stimulating hormone stimulus
- Pfemale gamete generation
- Pfemale gonad development
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
G protein-coupled signalling
- ·G protein-coupled receptor for follitropin, the follicle-stimulating hormone (PubMed:118…
- ·G protein-coupled peptide receptor activity
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
- ·G protein-coupled receptor signaling pathway
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
7 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Follicle stimulating hormone receptor agonist
Indicated for Hypogonadism, Infertility, Male, Primary Ovarian Insufficiency
Follicle stimulating hormone receptor agonist
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene FSHR
Gene-level evidence surfaced through the gene FSHRthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
7 compounds recorded · 7 approved
View all recorded compounds (7)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (8)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationMuscle-derived myostatin is a major endocrine driver of follicle-stimulating hormone synthesis.
- New publicationThe satiety hormone cholecystokinin gates reproduction in fish by controlling gonadotropin secretion.
- New publicationClustering Identifies Subtypes With Different Phenotypic Characteristics in Women With Polycystic Ovary Syndrome.
- New publicationFollicle stimulating hormone controls granulosa cell glutamine synthesis to regulate ovulation.
- New publicationHormone Regulation in Testicular Development and Function.
- New publicationDisturbed sex hormone milieu in males and females with major depressive disorder and low-grade inflammation.
- New publicationMetabolic characteristics of obese patients with polycystic ovarian syndrome: a meta-analysis.
- New publicationGonadotropin-Releasing Hormone Receptor (GnRHR) and Hypogonadotropic Hypogonadism.
- New publicationFollicle-stimulating hormone orchestrates glucose-stimulated insulin secretion of pancreatic islets.
- New publicationInfluence of Vitamin D on the Incidence of Metabolic Syndrome and Hormonal Balance in Patients with Polycystic Ovary Syndrome.
- Regulatory approval
Approval: Rekovelle (EMA)
- Regulatory approval
Approval: Elonva (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.